Isoshine 20 Softgel Capsule contains isotretinoin 20 mg, a retinoid derivative primarily indicated for the treatment of severe recalcitrant nodular acne that is unresponsive to conventional therapies such as systemic antibiotics and topical treatments. Isotretinoin acts by reducing sebaceous gland size and sebum production, inhibiting the growth of acne-causing bacteria, and exerting anti-inflammatory effects, thereby addressing multiple pathogenic factors of acne vulgaris. The softgel formulation ensures optimal bioavailability and ease of administration. Isoshine 20 should be prescribed with caution due to its well-documented teratogenic potential; strict adherence to pregnancy prevention programs is mandatory for women of childbearing potential. Common adverse effects include dryness of the skin, lips, and mucous membranes, cheilitis, and transient elevations in liver enzymes and lipid profiles, necessitating regular monitoring during therapy. Patients should avoid vitamin A supplementation and use effective contraception throughout treatment and for at least one month after discontinuation. Isoshine 20 Softgel Capsule is contraindicated in pregnancy, hypersensitivity to isotretinoin, and patients with hepatic impairment or hyperlipidemia. It is essential to follow dosing guidelines and monitor patients closely to optimize therapeutic outcomes and minimize risks.